Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Other Non-Current Liabilities (2022 - 2024)

Historic Other Non-Current Liabilities for Rhythm Pharmaceuticals (RYTM) over the last 3 years, with Q2 2024 value amounting to $35.6 million.

  • Rhythm Pharmaceuticals' Other Non-Current Liabilities rose 259666.67% to $35.6 million in Q2 2024 from the same period last year, while for Jun 2024 it was $35.6 million, marking a year-over-year increase of 259666.67%. This contributed to the annual value of $1.2 million for FY2023, which is 1417.91% down from last year.
  • Rhythm Pharmaceuticals' Other Non-Current Liabilities amounted to $35.6 million in Q2 2024, which was up 259666.67% from $34.6 million recorded in Q1 2024.
  • In the past 5 years, Rhythm Pharmaceuticals' Other Non-Current Liabilities ranged from a high of $35.6 million in Q2 2024 and a low of $1000.0 during Q1 2023
  • Its 3-year average for Other Non-Current Liabilities is $8.6 million, with a median of $1.3 million in 2023.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first tumbled by 1698.11% in 2023, then surged by 345970000.0% in 2024.
  • Over the past 3 years, Rhythm Pharmaceuticals' Other Non-Current Liabilities (Quarter) stood at $1.3 million in 2022, then dropped by 14.18% to $1.2 million in 2023, then surged by 2995.3% to $35.6 million in 2024.
  • Its last three reported values are $35.6 million in Q2 2024, $34.6 million for Q1 2024, and $1.2 million during Q4 2023.